Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.
Persistent high residual inflammatory risk is associated with an increased major adverse cardiac and cerebrovascular accident risk in patients undergoing percutaneous coronary intervention who have a low baseline low-density lipoprotein level.
Investigators sought to determine whether lipoprotein(a) and oxidized phospholipids on apolipoprotein B-100 levels can affect disease activity, disease progression, and clinical events in patients with aortic stenosis.
Investigators used Mendelian randomization analysis to determine the amount of lipoprotein(a) reduction needed to match the effect on coronary heart disease outcomes that lowering low-density lipoprotein cholesterol has.
An HDL apolipoproteomic score was associated with the presence of coronary artery disease, independent of other conventional cardiovascular risk factors.
The FDA has approved Praluent (alirocumab; Sanofi and Regeneron), a PCSK9 inhibitor, to reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Substituting red meat with high-quality plant protein sources, but not with fish or low-quality carbohydrates, leads to greater improvements in blood lipids and lipoproteins.
Results reflect a higher clearance of small atherogenic very-low-density lipoproteins remnant particles, which might contribute to cardiovascular risk reduction beyond low-density lipoprotein cholesterol lowering in clinical routine.
